Health Care [ 6/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.
Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors.
It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC.
The company is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | -0.75 Decreased by -27.12% | -0.41 Decreased by -82.93% |
| Jun 5, 25 | -0.66 Decreased by -11.86% | -0.60 Decreased by -9.98% |
| Feb 25, 25 | -0.22 Increased by +60.00% | -0.64 Increased by +65.49% |
| Nov 7, 24 | -0.63 Decreased by -26.00% | -0.63 |
| Aug 8, 24 | -0.59 Decreased by -11.32% | -0.63 Increased by +6.35% |
| May 2, 24 | -0.59 Decreased by -18.00% | -0.55 Decreased by -7.27% |
| Feb 27, 24 | -0.55 Decreased by -12.24% | -0.55 |
| Nov 2, 23 | -0.50 Increased by +5.66% | -0.55 Increased by +9.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 15.29 M Increased by +N/A% | -66.12 M Decreased by -30.07% | Decreased by -432.51% Decreased by N/A% |
| Mar 31, 25 | 14.11 M Increased by +N/A% | -57.43 M Decreased by -15.96% | Decreased by -407.07% Decreased by N/A% |
| Dec 31, 24 | 53.88 M Increased by +4.14 K% | -19.22 M Increased by +55.09% | Decreased by -35.66% Increased by +98.94% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -54.40 M Decreased by -40.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -50.84 M Decreased by -36.75% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -49.52 M Decreased by -59.75% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 1.27 M Increased by +N/A% | -42.79 M Decreased by -28.32% | Decreased by -3.37 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -38.60 M Decreased by -8.73% | Decreased by N/A% Decreased by N/A% |